Home > Oncology > ESMO 2020 > Lung Cancer > Atezolizumab/bevacizumab for non-squamous NSCLC with high PD-L1 expression

Atezolizumab/bevacizumab for non-squamous NSCLC with high PD-L1 expression


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22
Conference
ESMO 2020
First-line atezolizumab plus bevacizumab showed promising results in patients with non-squamous, PD-L1-positive non-small cell lung cancer (NSCLC). Preclinical models have shown that bevacizumab enhances the antitumor activity of PD-1/PD-L1 antibodies [1]. Therefore, the single-arm phase 2 WJOG@Be Study evaluated the clinical benefits of adding bevacizumab (15 mg/kg every 3 weeks ) to atezolizumab (1,200 mg every 3 weeks) in the first-line [2]. Patients were eligible if they had pathologically confirmed advanced non-squamous NSCLC without any EGFR/ALK/ROS1 alterations, and PD-L1 tumour proportion score ≥50%. A total of 39 patients were enrolled and treated until progression. Objective response rate was 64.1% (25/39), all partial responses. Median progression-free survival (PFS) was 15.9 months and PFS rate at 1 year was 54.9%. Overall survival rate at 1 year was 70.6%. The treatment was discontinued in 19 patients, 17 due...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on